BioNTech to buy T-cell receptor facility and platform from Gilead Sciences

4 days ago 3
PR Distribution

Shares of BioNTech SE BNTX, -1.03% were down 2.4% successful premarket trading connected Monday aft the institution said it plans to bargain 1 of Gilead Sciences Inc.'s GILD, -0.32% objective manufacturing facilities and its level for T-cell receptor therapies. The companies did not disclose fiscal presumption of the deal, saying lone that BioNTech volition marque a one-time outgo for the level and the installation successful Gaithersburg, MD. The tract volition beryllium utilized to enactment objective trials successful the U.S.; each employees astatine the installation volition beryllium offered jobs astatine BioNTech, which is simply a German biotechnology company. The caller tract is expected to beryllium portion of BioNTech's enactment processing caller crab therapies. BioNTech has go a well-known sanction extracurricular of biotech circles since processing a COVID-19 vaccine with Pfizer Inc. PFE, -0.62%. Shares of BioNTech person gained 183.9% truthful acold this year, portion the S&P 500 SPX, -1.66% is up 15.2%.

Read Entire Article